Fig. 2
Immune-related gene modulation by epigenetic drugs in melanoma. Modulation of 731 genes, grouped into 21 functional classes, was assessed by the NanoString Cancer Immune panel upon treatment with 4 epigenetic drugs and with Abemaciclib of ten melanoma cell lines with the indicated mutational and differentiation profiles. The overall modulatory activity of all drugs on each gene class was visualized by two ad-hoc developed, color-coded metrics described at the bottom of the Figure. Up- or down-modulation of each gene by any drug was defined on the basis of a Treated/Control ratio > |1.5|. *: these two cell lines were treated with decitabine, the active metabolite of guadecitabine